Immune checkpoint inhibitors (ICI) have improved prognosis in advanced malignancies but may be associated with extensive ocular immune-related adverse events (irAEs) that may be sight-threatening. Although ocular side effects account for 1% of total adverse events, they are becoming more commonplace as more people undergo treatment with ICI. This chapter aims to identify the presentation, characteristics, and management of ocular irAEs. Prompt recognition and management of ocular irAEs can improve patient care and outcomes.
- Checkpoint immunotherapy
- CTLA-4 inhibitors
- Immune-related adverse events
- Ocular oncology
ASJC Scopus subject areas